Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Aug 2;22(23):5682–5687. doi: 10.1158/1078-0432.CCR-16-1031

Figure 2.

Figure 2

Representative CAT scans demonstrating activity (ie, partial response) of nivolumab in Patient #1 (ie, POLE-ultra-mutated). Left panels: Pretreatment images with baseline measurements of two representative metastatic tumor deposits [ie, mass abutting the pancreatic tail in the gastro-splenic ligament (Upper Left Panel) and mass involving the bladder dome wall (Lower Left Panel). Middle panels: Regression of the metastatic tumor deposits described above three months after treatment initiation. Right panels: regression (Upper Right) and disappearance (Lower Right) of the metastatic tumor deposits described above seven months after treatment initiation with nivolumab.